Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

19.8%

228 terminated/withdrawn out of 1151 trials

Success Rate

72.2%

-14.4% vs industry average

Late-Stage Pipeline

12%

142 trials in Phase 3/4

Results Transparency

53%

314 of 591 completed trials have results

Key Signals

171 recruiting314 with results159 terminated69 withdrawn

Enrollment Performance

Analytics

N/A

442(50.5%)

Phase 2

163(18.6%)

Phase 1

111(12.7%)

Phase 4

103(11.8%)

Phase 3

39(4.5%)

Early Phase 1

17(1.9%)

875Total

N/A(442)

Phase 2(163)

Phase 1(111)

Phase 4(103)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1151)

Showing 20 of 1151 trials

NCT06994442Phase 3Recruiting

Optimizing Pain Treatment in Children On Mechanical Ventilation

Role: lead

NCT06818734Not ApplicableRecruiting

Implementation of a Clinical Decision Support Tool for Postpartum Depression

Role: lead

NCT07580963Not ApplicableNot Yet Recruiting

Stent Related Symptoms Defined by Ureteral Stent Symptom Questionnaire in Patients With Image-Informed Ureteral Stent Lengths

Role: lead

NCT05019027Phase 4Completed

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

Role: lead

NCT05345444Not ApplicableActive Not Recruiting

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

Role: lead

NCT07046429Not ApplicableRecruiting

Affect of Melatonin on Sleep and Cognition in Cirrhosis

Role: lead

NCT02316314Recruiting

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

Role: lead

NCT07386548Not ApplicableRecruiting

Biologic Injection For Adults With Lumbar Disc Herniation

Role: lead

NCT05024097Phase 2Recruiting

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Role: lead

NCT07536399Phase 3Recruiting

Biologic Augmentation of TMJ Arthroscopy Using BMAC

Role: lead

NCT03304080Phase 1Active Not Recruiting

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Role: collaborator

NCT06039930Not ApplicableRecruiting

Tele-PROTECT Therapy: Effectiveness, Empowerment, and Implementation

Role: lead

NCT06994325Not ApplicableActive Not Recruiting

Testing the CHAT Program for Patients With Heart Failure

Role: lead

NCT06810622Not ApplicableRecruiting

NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities

Role: collaborator

NCT07724418Phase 4Not Yet Recruiting

Split Face Study of the Duration of Local Anesthetics - Fifth Arm

Role: lead

NCT07725406Phase 1Not Yet Recruiting

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Role: lead

NCT05820295Not ApplicableCompleted

Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination

Role: lead

NCT06225986Not ApplicableCompleted

Living Memory Home-4-Dementia Care Pairs

Role: lead

NCT07257484Phase 4Recruiting

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Role: lead

NCT05416372Not ApplicableSuspended

Engaging Religious Leaders to Reduce Blood Pressures in Tanzanian Communities

Role: lead